10 Worst ARK Stocks To Buy According To Short Sellers

3. CRISPR Therapeutics AG (NASDAQ:CRSP)

Short Interest as % of  Shares Outstanding: 20.16%

Number of Hedge Fund Investors In Q2 2024: 29

Ark Invest’s Q2 2024 Stake: $420 million

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the earliest movers in the new age gene sequencing industry. The firm develops medicines through its proprietary gene sequencing technology that allows for targeted DNA changes. The technology provides CRISPR Therapeutics AG (NASDAQ:CRSP) a wide moat within its industry, but a lack of diversification means that the firm and its partners have to develop medicines with the platform to generate revenue. CRISPR Therapeutics AG (NASDAQ:CRSP) is operating in one of the fastest growing markets in the world, which is expected to grow at a compounded annual growth rate of 22.3% between 2022 and 2027 for a final value of $9.2 billion. Its trailing twelve month revenue is $200 million, which creates a wide moat for CRISPR Therapeutics AG (NASDAQ:CRSP) to capture the market. So far, the firm has relied on royalty payments, particularly from Vertex due to the sickle cell treatment. CRISPR Therapeutics AG (NASDAQ:CRSP) received $170 million in 2023 and is eligible for another $130 million.